During the after-hours trading session, SkyWater Technology, Inc.’s (NASDAQ: SKYT) share price had a significant boost, jumping 22.44% to $10.86. The rise came after the completion of a major strategic acquisition—Infineon’s U.S.-based semiconductor manufacturing plant, Fab 25 in Austin, Texas—and the announcement of second-quarter financial results that exceeded projections. The Acquisition Of Fab 25 Will

After strong second-quarter earnings, shares of Astera Labs, Inc. (NASDAQ: ALAB) saw significant movement in extended trading. After hours, ALAB’s shares rose 17.31% to settle at $159.00. The business reported a 20% sequential increase in revenue, which significantly improved profitability and operating cash flow. Growth in Revenue and Key Financial Data Astera Labs made $191.9

In the most recent session, shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) have had a notable surge, rising 14.89% to trade at $5.17. The biotechnology company saw a surge with the release of positive results from ongoing clinical trials and the confirmation of regulatory alignment with the European Medicines Agency (EMA) for its lead

Following news of a possible takeover deal, Chart Industries, Inc.’s (NYSE: GTLS) stock saw a sharp increase on Monday. After-hours trading saw GTLS shares rise 18.28% to $203.02. According to the Financial Times, the rise coincides with Baker Hughes, a major player in the oil and gas equipment industry, apparently nearing completion of a $13.6

Following the announcement of noteworthy clinical trial advancements, Celcuity Inc. (NASDAQ: CELC) stock saw a surge in value. The CELC stock was trading at $38.31 as of the most recent check, representing a remarkable 178.18% increase. The company’s Phase 3 VIKTORIA-1 trial’s PIK3CA wild-type group showed encouraging topline findings. After advancement on a CDK4/6 inhibitor

As of the most recent check, OFA Group, Inc. (NASDAQ: OFAL) saw a notable market response, with its shares rising 23.41% to $2.13. The company’s introduction of a digital asset treasury plan to improve its financial processes was followed by a spike in the stock price. The announcement was made in conjunction with OFA Group’s

Investor sentiment surged in the pre-market session as shares of Lifezone Metals Limited (NYSE: LZM) rose over 10%, reaching $4.90 as of the latest check. This sharp upward movement follows a strategic acquisition that positions the company at the forefront of a major nickel development. Lifezone has finalized a definitive agreement with BHP Billiton (UK)

Shares of Helius Medical Technologies, Inc. (NASDAQ: HSDT) jumped 90.22% to $16.93 in pre-market trading following the company’s announcement of very positive Stroke Registrational Program (SRP) findings. Breakthrough Clinical Results from PoNS Therapy Helius Medical, operating under the FDA’s Breakthrough Device Designation, announced positive results from its Portable Neuromodulation Stimulator (PoNS) Stroke Registrational Program. In

Lucid Group, Inc. (NASDAQ: LCID) witnessed a substantial surge in its stock price, climbing 44.98% to trade at $3.32 as of the latest check. Following the company’s announcement of a next-generation premium global robotaxi project in partnership with Nuro, Inc. and Uber Technologies, Inc. (NYSE: UBER), LCID stock saw a dramatic increase in value. In

The stock price of Nuwellis, Inc. (NASDAQ: NUWE) surged 156.71% to $17.70 during pre-market activity. The sharp rise in value, which marked a shift in the company’s technological and strategic orientation, was caused by a newly granted U.S. patent. Breakthrough Patent Strengthens Technological Edge On July 15, 2025, Nuwellis was officially issued U.S. Patent No.

Amprius Technologies, Inc.’s stock (NYSE: AMPX) went up 10.03% to $7.41 as of today’s latest check, after the company’s selection for the 2025 cohort of the Amazon Devices Climate Tech Accelerator. Recognition for SiCore Battery Platform As part of Amazon’s wider commitment under The Climate Pledge, this program encourages solutions that reduce carbon emissions throughout

Daré Bioscience, Inc. (NASDAQ: DARE) shares surged by 74.16% to $4.38 as of the last check during morning trading following the release of encouraging interim data from a Phase 3 clinical trial. Positive Interim Analysis Supports Efficacy and Safety The trial evaluates the contraceptive effectiveness, safety, and acceptability of Ovaprene, DARE’s investigational monthly, hormone-free intravaginal